The Bcl-2/Bcl-XL/Bcl-w Inhibitor, Navitoclax, Enhances the Activity of Chemotherapeutic Agents <i>In Vitro</i> and <i>In Vivo</i>
Jun Chen(Jilin University), Steven W. Elmore(AbbVie (United States)), Yu Shen(University of Florida), Sha Jin(AbbVie (United States)), Scott Ackler(AbbVie (United States)), Morey L. Smith(AbbVie (United States)), Deepak Sampath, Vivek Abraham(University of Chicago), Bernard A. Liu(University of Chicago), Heather Maecker, Xiaoyu Lin(AbbVie (United States)), Joel D. Leverson(AbbVie (United States)), Xiaoli Huang(Sichuan Agricultural University), Haichao Zhang(Abbott Fund), Stephen K. Tahir(Abbott Fund), Alexander R. Shoemaker(Abbott Fund), Saul H. Rosenberg(Abbott Fund), Paul Nimmer(Abbott Fund), Michael J. Mitten(Abbott Fund), Chris Tse(AbbVie (United States))
Cited by 149
Related Papers
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
|Nature Medicine|2013|3k
ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
|Cancer Research|2008|2k